Communities

We work to continuously refine our specialty areas and treatments, investing in medical innovations that bring a brighter future. In addition to this, we are constantly committed to activities and initiatives within disease communities which support awareness and better research in areas of need, particularly within rare diseases.
Arrigo Prize: Committed to Excellence in Research
Established in 2000 in memory of Arrigo Recordati, this international recognition aims to promote scientific research. The 2024 Award was dedicated to the promotion and recognition of excellence in research within paediatric oncology, specifically neuroblastoma.
The prize awards €100,000 to an early-career researcher who has particularly stood out for formulating an innovative research project. The winner is selected by an independent panel formed of global experts.
Filling the educational gap in rare diseases
Recordati Rare Diseases Foundation aims to organise training on rare diseases to improve diagnosis and spread currently available knowledge on therapeutic options.  The organisation promotes scientific sharing of experience and knowledge between centres of expertise and specialists across the globe.  Every year, the Foundation proposes tailored face to face courses that aim to provide physicians, worldwide, with clinically useful and the most up-to-date information concerning current knowledge and recommendations for care.  The Foundation has delivered over 75 courses to over 3000 healthcare professionals since its creation. 
Read more
Shining a light on the burden of a rare disease like Cushing’s syndrome

This is Cushing is an award-winning* global awareness campaign which aims to spread education on Cushing’s syndrome. The campaign was designed together with the award-winning photographer Stefano Schirato and Federico II University of Naples Full Professors of Endocrinology, Annamaria Colao and Rosario Pivonello, to capture a moment in time of someone living with Cushing’s syndrome.

 

Cushing’s syndrome is a rare endocrine disorder caused by a chronic exposure to excessive levels of cortisol affecting less than 1 in 10,000 people in the European Union, which is equivalent to fewer than 51,000 patients. The disease is associated with significant morbidity and mortality due to cardiovascular and metabolic complications. In addition to the physical features, psychiatric manifestations are also a significant part of the disease which drastically affect patients’ quality of life.

*Winner of the 2023 PMEA Award for Patient Centricity.
Unique partner with scientific societies
Recordati Rare Diseases is proud of its Strong and unique partnership with international scientific societies. For Qarziba, evidence generations for current and future potential indications are done through independent academic studies lead by SIOPEN.

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

このサイトを離れ、別の外部サイトへ移動しようとしています。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

Recordatirarediseases.comを離れます。

これより先はRecordatiが運営するウェブサイトとなります。
よろしければ「続ける」をクリックしてください。

続ける
キャンセル

あなたは医療関係者ですか?

このページでは、国内の医療関係者（医師・薬剤師等）の方を対象に情報を提供しています。一般の方や国外の医療関係者に対するものではございませんのでご了承ください。
はい
いいえ
Recordati for the planet
A clean environment is essential for people’s well-being: the health of the planet and the health of people is tightly interconnected. Environmental elements, such as air, water, land and climate, all have an impact on the well-being of humans. Placing a focus on people’s health and being sustainable therefore also means prioritising environmental protection and a responsibility towards future generations. This is why the Group ensures that it conducts business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the expectations of stakeholders.
Recordati for the community
We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative, an essential part of a healthy business capable of growth but at the same time able to support and develop the community in which it operates and make its employees proud.
Value and diversity of our people
At Recordati, we believe in equal opportunities and we guarantee that everyone can achieve their potential. We see diversity as a value and will not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics. At Recordati, we work hard to create a safe and inclusive work environment, where we all have our rights to physical and psychological integrity respected on a daily basis, as well as our right to freedom of opinion and association. We recognise that we each have a role to play in the success of our business and we implement staff development policies through which everyone’s contribution and achievements can be appropriately rewarded.
Multiple opportunities
Recordati is uniquely structured to bring treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

 

He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.

 

Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.

Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region, Head of Global Endocrinology Franchise

Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.

 

Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Mohamed Ladha
President and General Manager, North America

Mohamed Ladha is the President and General Manager at Recordati Rare Diseases where he is   responsible for the US and Canadian business. During his career,  Mohamed has held numerous leadership positions globally in hematology/oncology and specialty care to oversee business in the US, Canada, EU, China, Emerging Markets, and Japan.

 

Mohamed  joins Recordati Rare Diseases from Oncopeptides, where he was the General Manager and Executive Vice President for the US Region Business Unit. Prior to Oncopeptides, he served in a series of leadership positions of increasing responsibility at companies including Vertex Pharmaceuticals, Pfizer, Schering-Plough, Merck & Company, Hospira, ARIAD Pharmaceuticals, Takeda Oncology, and Tocagen. He started his career in basic science research focused in oncology at the Dana-Farber Cancer Institute.

 

Mohamed graduated from Hampshire College with a Bachelor of Arts degree. He also holds professional/graduate degrees from Harvard University’s Kennedy School of Government and Northwestern University’s Kellogg School of Management.

 

Changing to first name to be consistent with bio below, also feel that first name as opposed to Mr has a more informal and friendly tone.   [EC1]

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

 

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

 

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site